KRAS and non-small cell lung carcinoma: Sotorasib (AMG 510), a KRAS (G12C) inhibitor developed by Amgen®, produced significant results in phase 1 clinical trial for non-small cell lung cancer, rapidly emerging as the next new drug for lung cancer.